E85 GTS brings advanced guidance to integrated prostate pathway in Leeds
At St James’s University Hospital, Leeds, Dr Oliver Hulson is developing a more integrated pathway for men with suspected prostate cancer, bringing imaging, decision making and biopsy closer together within a streamlined clinical model. A key focus of this pathway is the potential use of Esaote’s new MyLab E85 GTS (Guided Therapy Solutions) platform, combined with UroFusion software, to support a one-stop approach incorporating high-quality ultrasound, MRI-informed targeting and same-day fusion biopsy.
Designed specifically for clinicians involved in prostate intervention, the MyLab E85 GTS builds on Esaote’s premium ultrasound architecture to deliver a more advanced, therapy-oriented workflow. As demand grows for precision and efficiency in prostate diagnostics, the system is intended to support greater confidence during targeted biopsy procedures.
High-quality imaging remains fundamental to prostate diagnostics. Accurate visualisation of the gland, clear anatomical definition and reliable real-time guidance are essential when correlating MRI findings with live ultrasound during biopsy. Esaote’s premium ultrasound technology is designed to provide the imaging performance required for demanding prostate applications, helping clinicians improve lesion targeting and procedural confidence.
The Leeds pathway begins with MRI prostate assessment, supported by Lucida’s Pi software as an AI-assisted secondary read. The software is designed to identify suspicious lesions, outline the prostate, calculate gland volume and provide additional risk information to support radiological review and biopsy planning. This information can then be used during the interventional stage, where fusion-guided biopsy becomes the central procedural step.
At the heart of this workflow is Esaote’s UroFusion software, which combines MRI datasets with live ultrasound imaging to support targeted prostate biopsy. UroFusion includes automatic MRI prostate contouring and segmentation, automatic MRI-ultrasound synchronisation, the ability to combine multiple mpMRI series and automatic biopsy mapping within a 3D prostate model. Automated reporting further supports a structured and reproducible workflow. The platform can be used for both transperineal and transrectal approaches, helping clinicians standardise procedures and maintain clear documentation.
A particularly innovative aspect of the MyLab E85 GTS is its integration with Prostate Attention Map (PAM). PAM is designed to automatically analyse prostate mpMRI volumes and identify suspicious regions of interest, feeding this information directly into the UroFusion environment. By combining AI-supported lesion identification with fusion-guided biopsy, the system has the potential to enhance targeting confidence and procedural efficiency while remaining intuitive for clinicians to use.
Beyond prostate applications, the system offers broader value across Radiology departments. Esaote’s premium ultrasound platforms are designed for use in multiple clinical areas, enabling departments to maximise scanner utilisation and support a wider range of examinations when the system is not being used for prostate procedures.
For centres looking to develop more connected prostate pathways, the MyLab E85 GTS, together with UroFusion and PAM, represents a significant step towards a more integrated approach. By combining advanced ultrasound imaging, AI-supported target identification and fusion-guided intervention within a single workflow, the platform supports pathways that are both clinically robust and operationally efficient. In Leeds, this model is helping shape the future of prostate diagnostics and intervention.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.
